Literature DB >> 24997143

Complete bilateral ophthalmoplegia with unilateral facial palsy in a child with anti-GQ1b syndrome.

Hina Kauser1, Puneet Jain, Suvasini Sharma, Satinder Aneja.   

Abstract

The classical phenotype of Miller Fisher syndrome is characterized by ophthalmoplegia, ataxia and areflexia. However, less extensive forms have been described. The authors report a 14-y-old boy with positive anti-GQ1b antibodies with unusual clinical findings. He presented with headache, double vision and vomiting for 7 d. Examination revealed complete opththalmoplegia, right lower-motor-neuron facial palsy, no limb weakness or cerebellar signs and normal fundus. CSF examination and MRI brain were normal. Electrophysiological studies showed normal limb nerve conduction studies, low CMAP amplitude of right facial nerve, abnormal blink reflex and negative repetitive-nerve-stimulation test. Anti-GQ1b antibodies were positive. The child was managed conservatively with gradual complete recovery. The patients with positive anti-GQ1b antibodies who do not demonstrate the full complement of the Miller Fisher syndrome triad have been reported previously. However, unilateral facial palsy has not been reported previously. This report further expands the phenotypic spectrum of anti-GQ1b syndrome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24997143     DOI: 10.1007/s12098-014-1514-4

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  10 in total

1.  Clinical features and prognosis of Miller Fisher syndrome.

Authors:  M Mori; S Kuwabara; T Fukutake; N Yuki; T Hattori
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

2.  Recurrent facial nerve palsy associated with anti-GQ1b IgG antibodies.

Authors:  Filippo Greco; Maria Luisa Barbagallo; Rosanna Guglielmino; Giovanni Sorge
Journal:  Brain Dev       Date:  2008-04-18       Impact factor: 1.961

3.  Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry.

Authors:  M Koga; M Gilbert; J Li; S Koike; M Takahashi; K Furukawa; K Hirata; N Yuki
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

4.  Anti-GQ1b IgG antibody syndrome: clinical and immunological range.

Authors:  M Odaka; N Yuki; K Hirata
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

5.  Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher's syndromes.

Authors:  M Koga; N Yuki; M Takahashi; K Saito; K Hirata
Journal:  J Neuroimmunol       Date:  1998-01       Impact factor: 3.478

6.  Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases.

Authors:  M Ito; S Kuwabara; M Odaka; S Misawa; M Koga; K Hirata; N Yuki
Journal:  J Neurol       Date:  2008-02-18       Impact factor: 4.849

7.  Isolated cranial neuropathy associated with anti-glycolipid antibodies.

Authors:  Makoto Kunishige; Takao Mitsui; Hiide Yoshino; Atsuko Asano; Miho Tsuruo; Itsuro Endo; Fumikazu Yagi; Toshio Matsumoto
Journal:  J Neurol Sci       Date:  2004-10-15       Impact factor: 3.181

Review 8.  Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome.

Authors:  Nortina Shahrizaila; Nobuhiro Yuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-15       Impact factor: 10.154

Review 9.  Clinical and immunological spectrum of the Miller Fisher syndrome.

Authors:  Y L Lo
Journal:  Muscle Nerve       Date:  2007-11       Impact factor: 3.217

10.  Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles.

Authors:  Jing-Xia Liu; Hugh J Willison; Fatima Pedrosa-Domellöf
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-28       Impact factor: 4.799

  10 in total
  1 in total

1.  Anti-GQ1b antibody syndrome presenting with visual deterioration as the initial symptom: A case report.

Authors:  Teng Zhao; Yuyan Deng; Ying Ding; Rensheng Zhang; Chunkui Zhou; Weihong Lin
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.